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We performed a retrospective study to identify pretransplantation risk factors for steroid-refractory (SR)
acute graft-versus host disease (aGVHD) after allogeneic stem cell transplantation from matched donors in
630 adult patients who underwent transplantation at our center between 2000 and 2012. The cumulative
incidence (CI) of SR aGVHD was 11.3%  2.3%. The identiﬁed independent risk factors were matched unrelated
donor (hazard ratio [HR], 2.52; P ¼ .001), female donor for male recipient (HR, 1.84; P ¼ .023) and absence of
antithymocyte globulin (HR, 2.02; P ¼ .005). Three risk groups were deﬁned according to the presence of
these risk factors. In the whole cohort, the CI of SR aGVHD was 3.5%  1.7% in the low-risk group (0 risk factor,
n ¼ 115), 9.3%  1.6% in the intermediate-risk group (1 risk factor, n ¼ 323), and 19.3%  2.9% in the high-risk
group (2 or 3 risk factors, n ¼ 192). Our study suggests that pretransplantation characteristics might help
identify patients at high risk for SR aGVHD. A risk adapted ﬁrst-line treatment of aGVHD could be evaluated in
those patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus host disease (aGVHD) remains the
most frequent and challenging complication after allogeneic
stem cell transplantation (allo-SCT). The most consistently
reported risk factors are well deﬁned and include HLA-
mismatched donor, HLA-matched unrelated donor, older
patient age, a female donor for a male recipient, prior
alloimmunization of the donor, and type of graft-versus-host
disease (GVHD) prophylaxis [1-3]. Less consistently reported
risk factors include higher intensity of the conditioning
regimen with irradiation, older donor age, recipientedgments on page 864.
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ty for Blood and Marrow Transplantation.cytomegalovirus (CMV) seropositivity, and use of peripheral
blood (PB) stem cells [1-3].
Steroid-refractory (SR) aGVHD is of particular interest
because of its very poor prognosis, with a median survival of
6 months and a long-term survival ranging from 20% to 30%
[4,5]. Based on these results, several studies have sought to
identify risk factors for poor outcome at the onset of aGVHD.
Westin et al. [6] identiﬁed grade III and IV and hyperacute
(before day 14) aGVHD as predictors for SR aGVHD. Robin
et al. [7] reported that initial liver involvement was a clinical
predictor of poor outcome, andMcMillan et al. [8] proposed a
novel aGVHD risk score based on severity of skin, gut, and
liver involvement. More recently, Castilla-Llorente et al. [9]
identiﬁed steroid resistance, age > 18 years, increased
serum bilirubin, and overt gastrointestinal bleeding as sig-
niﬁcant risk factors for mortality after stage 3 and 4 gut
aGVHD. Unfortunately, the lack of satisfactory drugs to treat
Table 1
Patient and Transplantation Characteristics of the Study Population
(n ¼ 630)
Characteristics n (%)
Age at transplantation, median (range), yr 50 (18-67)
Year of transplantation, median 2007
2000-2003 124 (19.7)
2004-2006 137 (21.7)
2007-2009 170 (27)
2010-2012 199 (31.6)
ABO incompatibility
None 334 (53)
Major 99 (15.7)
Minor 115 (18.2)
Bidirectional 33 (5.2)
Missing data 49 (7.9)
Recipient sex
Male 411 (65.2)
Female 219 (34.8)
Female donor for male recipient 151 (24)
Recipient/donor CMV status
R/D 238 (37.8)
R/Dþ 77 (12.2)
Rþ/D 121 (19.2)
Rþ/Dþ 191 (30.3)
Missing data 3 (0.5)
Diseases
AML 229 (36.4)
MDS 46 (7.3)
ALL 104 (16.5)
NHL 76 (12.1)
HD 18 (2.8)
MM 78 (12.4)
AA 19 (3.1)
CLL 28 (4.4)
CML 18 (2.8)
MPS 14 (2.2)
Status at transplantation
CR1, PR1, or CP 290 (46)
>CR1, >PR1, or AP 207 (32.9)
Untreated 37 (5.9)
Refractory 96 (15.2)
Conditioning regimen*
NMA 77 (12.2)
RIC 296 (47)
MAC 257 (40.8)
ATGy
Yes 326 (51.7)
No 304 (48.3)
Dose of ATGz
Median dose, mg/kg 5
2.5 mg/kgx 70 (21.5)
5 mg/kg 200 (61.3)
7.5 mg/kgx 18 (5.5)
10 mg/kg 28 (8.6)
Missing data 10 (3.1)
ATG, Thymoglobulin 8
ATG-Fresenius 1
Horse ATG 1
Donor
Matched related 363 (57.6)
Matched unrelated 267 (42.4)
Source of stem cells
PB 441 (70)
BM 188 (29.8)
Missing data 1 (0.2)
Median CD34þ cells in the graft, median
(range)
5.4  106 (.6-31.9)
Missing data 17 (2.7)
GVHD prophylaxis
CsA 173 (27.5)
CsAþMTX 343 (54.4)
(Continued)
Table 1
(continued)
Characteristics n (%)
CsAþMMF 106 (16.8)
Others 8 (1.3)
R indicates recipient; D, donor; AML, acute myeloid leukemia; MDS, mye-
lodysplastic syndromes; ALL, acute lymphoid leukemia; NHL, non-Hodgkin
lymphoma; HD, Hodgkin’s disease; MM, multiple myeloma; AA, aplastic
anemia; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia;
MPS, myeloproliferative syndromes; CR, complete remission; PR, partial
remission; CP, chronic phase; AP, accelerated phase; MTX, methotrexate;
MMF, mycophenolate mofetil.
* According to Bacigalupo et al. [15].
y Rabbit ATG (Thymoglobulin, n ¼ 324; ATG-Fresenius, n ¼ 1) or horse
ATG (n ¼ 1).
z Rabbit ATG, Thymoglobulin.
x Doses exclusively used in patients who underwent transplantation with
RIC regimen.
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dictors and a preventive strategy based on analysis of pre-
transplantation characteristics might also be relevant. As the
speciﬁc pretransplantation risk factors for SR aGVHD are not
as clearly deﬁned as for aGVHD, we conducted a retrospec-
tive study in adult patients who underwent transplantation
from matched related (MRD) or matched unrelated donors
(MUD) at our center between 2000 and 2012.
PATIENTS AND METHODS
Patients
This retrospective study included adult patients (18 years) who
received an allo-SCT from an MRD or MUD between January 1, 2000 and
December 31, 2012 at the university hospital of Bordeaux. All patient records
were reviewed to ensure the quality of data. To reduce heterogeneity of the
study population, patients who underwent transplantation from mis-
matched unrelated (n ¼ 76) or syngeneic (n ¼ 2) donors were excluded, as
well as patients who underwent transplantationwith cord blood (n¼ 94) or
in vitro T celledepleted grafts (n ¼ 2).
During the period of study, our transplantation policy was always to
favor a sibling donor over an unrelated donor, to use reduced-intensity
conditioning (RIC) or nonmyeloablative (NMA) regimens in patients >50
years or with signiﬁcant comorbidities, and to use myeloablative (MAC)
regimens in patients 50 or 55 years, according to ongoing protocols.
Antithymocyte globulin (ATG) was mostly used with RIC regimens; more
often with unrelated donors, but its use did not depend on the disease, nor
on the status of disease. No haplo-identical or mismatched related trans-
plantation was performed during the period of the study. MUD were
matched at the allele level (4 digits) for HLA-A, -B, -C, -DRB1, -DQB1. The HLA
typing method did not signiﬁcantly change during the period of the study.
Deﬁnitions
The clinical diagnosis of aGVHD was based on a combination of symp-
toms affecting the skin, the liver, and/or the gastrointestinal tract after
transplantation [10]. The diagnosis of aGVHD was supported by biopsy
whenever indicated and possible. To reduce heterogeneity, aGVHD occur-
ring after donor lymphocytes infusions were not included. The grading of
aGVHD was made according to the 1994 consensus conference [11]. First-
line systemic therapy with methylprednisolone or prednisone 2 mg/kg/
day was started in patients with grade II to IV aGVHD according to the
European Society for Blood and Marrow Transplantation e European Leu-
kemiaNet (EBMT-ELN) and American Society for Blood and Marrow Trans-
plantation (ASBMT) recommendations [5,12]. The initial dose was
maintained for 7 to 14 days and tapered off in responding patients. SR
aGVHD was deﬁned as aGVHD progressing after 3 to 5 days of treatment,
unchanged after 7 days, or in incomplete response after 14 days, according
to the recent EBMT-ELN and ASBMT recommendations [5,12]. Because the
study period began in 2000, we chose to retrospectively select SR aGVHD if
they clearly corresponded to 1 of the 3 clinical situations recently deﬁned by
the EBMT-ELN and ASBMT groups [5,12]. We did not consider the start of a
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Figure 1. Overall survival of the whole study population (n ¼ 630).
Table 2
Impact of aGVHD on OS in the Whole Study Population (n ¼ 630)
Acute GVHD No. of Patients HR 95% CI P Value
No aGVHD (reference) 409 1
Steroid-sensitive aGVHD 150 1.21 .92-1.58 .17
SR aGVHD 71 3.49 2.58-4.71 <.001
95% CI indicates 95% conﬁdence interval.
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our strategy was to continue steroids without taper for at least 2 weeks
during the second-line therapy. Cyclosporine (CsA) was also continued. The
second-line therapies were daclizumab (n ¼ 24), inolimomab (n ¼ 20),
basiliximab (n ¼ 3), rabbit ATG (n ¼ 16), mycophenolate mofetil (n ¼ 1),
methylprednisolone 5 mg/kg/day (n ¼ 1, with failure), and tacrolimus (n ¼
2). Four patients did not receive a second-line therapy because they quickly
died of multiorgan failure secondary to SR aGVHD, but all of them clearly
met the criteria for steroid refractoriness. Primary graft failurewas deﬁned as
lack of initial engraftment of donor cells without evidence of relapse or
progression [13,14]. Secondary graft failurewas deﬁned as loss of donor cells
after initial engraftment [13,14].
Statistical Analysis
Overall survival (OS) was calculated using the Kaplan-Meier estimate
from the date of transplantation to either the date of death from any cause or
last follow-up. Nonrelapse mortality (NRM), deﬁned as death without prior
relapse/progression, was calculated from the date of transplantation with
cumulative incidence (CI) curves in a competing risks setting with relapse/
progression as competing events. Acute GVHD was analyzed with CI in a
competing risks setting with second allo-SCT and death as competing
events. The date of aGVHD was deﬁned as the onset of ﬁrst-line systemic
therapy. The Gray test was used to compare CI curves. For multivariate
analysis, all variables associated with SR aGVHD with a P value <.15 by
univariate analysis were entered into a Fine-Gray model. Potential in-
teractions between cofactors included in the ﬁnal score have been tested.
The impact of aGVHD on OS was evaluated as a time-dependent variable in a
Cox proportional-hazards regression model. The cases with missing values
were excluded for univariate analysis. The variables considered were year of
transplantation (> versus 2007, median year), recipient age ( versus <50
years, median age), female versus male donor, female donor for male
recipient (FM) versus other combinations, MRD versus MUD, PB versus bone
marrow (BM) graft, prophylaxis of GVHD with CsA versus CsA þ metho-
trexate versus CsA þ mycophenolate mofetil versus others, MAC versus
RIC þ NMA regimen [15], ATG versus no ATG, number of CD34þ cells in the
graft > versus 5.4  106/kg (median number), early (ﬁrst complete
remission (CR1), ﬁrst partial remission (PR1), chronic phase, or untreated)
versus advanced disease, disease (myeloid malignancies versus others),
CMV-seropositive versus seronegative recipient, CMV serostatus recipient
negative/donor negative versus other combinations, ABO incompatibility
(none versus minor versus major versus bidirectional). Numerous missing
data on ages of donors and absence of available pregnancy history in donors
precluded a relevant analysis of these variables. Statistical analyses were
performed with R 2.13.2 software packages (R Development Core Team,
Vienna, Austria).
RESULTS
Patient and Transplantation Characteristics
Six hundred thirty-six patients were identiﬁed. Six
patients were excluded because of missing data on aGVHD.
As a result, 630 patients were included in the present study.
During the period of the study, 17 patients underwent a
second allo-SCT for primary graft failure (n ¼ 5), secondary
graft failure (n ¼ 4), or relapse/progression (n ¼ 8). Patient
and transplantation characteristics are summarized in
Table 1.Survival and Acute GVHD
With a median follow-up of 56 months (range, 1 to 167),
the 5-year OS of the whole study population was 48.4% 
2.2% (Figure 1). The CI of aGVHD grade II to IV and grade III
and IV were 35.1%  3.7% and 18.3%  2.9%, respectively. As
shown in Table 2, SR aGVHD had a deleterious impact on OS
(hazard ratio [HR], 3.49; P ¼ .001) in contrast to steroid-
sensitive aGVHD (HR, 1.21; P ¼ .17).Steroid-Refractory Acute GVHD
SR aGVHD was diagnosed in 71 patients in whom initial
aGVHD began at a median time of 31 days (range, 8 to 152)
after transplantation. The maximum grade of aGVHD before
diagnosis of steroid refractoriness was III and IV in 69
patients and II in 2 patients. Sixty-eight patients had no ev-
idence of relapse/progression before the diagnosis of SR
aGVHD, whereas 3 patients were diagnosed 12, 22, and 30
days after relapse andwithdrawal of CsA. The CI of SR aGVHD
was 11.3%  2.3%. Patients with SR aGVHD had a median age
of 49 years (range, 18 to 67) and a median survival of 5
months. As shown in Figure 2, they had 1-year and 5-year OS
of 34.6%  5.7% and 21.2%  5.2%, respectively.
For the analysis of risk factors, NMA conditioning regi-
mens were merged with RIC regimens because of compara-
ble CI of SR aGVHD (9.1%  3.3% versus 9.4%  1.7%, P ¼ .92).
In univariate analysis, risk factors for SR aGVHD were MUD
(P¼ .001) and no ATG (P ¼ .01), with trends for MAC (P ¼ .06)
and FM (P ¼ .147). Other variables considered in univariate
analysis were year of transplantation (P ¼ .93), recipient age
(P ¼ .91), female versus male donor (P ¼ .77), recipient CMV
status (P ¼ .93), CMV serostatus recipient negative/donor
negative versus other combinations (P¼ .53), myeloid versus
other malignancies (P ¼ .31), early versus advanced diseases
(P ¼ .23), PB versus BM graft (P ¼ .98), number of CD34þ cells
in the graft (P¼ .36), ABO incompatibility (P¼ .85), and GVHD
prophylaxis (P ¼ .76).
In multivariate analysis performed in the whole cohort
(n¼ 630), risk factors for SR aGVHDwereMUD (HR, 2.52; P¼
.001), FM (HR,1.84; P¼ .023), and no ATG (HR, 2.02; P¼ .005)
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Figure 2. Overall survival of patients with SR aGVHD (n ¼ 71).
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relapse/progression added to second allo-SCT and death as
competing events for SR aGVHD, the same risk factors were
identiﬁed (MUD: HR, 2.70; P ¼ .001; FM: HR, 1.98; P ¼ .01;
and no ATG: HR, 2.08; P ¼ .003). Three risk groups were then
identiﬁed according to the number of pretransplantation risk
factors: a low-risk group with 0 risk factors (n ¼ 115), an
intermediate-risk group with 1 risk factor (n ¼ 323), and a
high-risk group with 2 (n ¼ 177) or 3 (n ¼ 15) risk factors.
Because the group with 3 risk factors was small, it was
merged with the group with 2 risk factors. In the whole
cohort, as shown in Table 4, the CI of SR aGVHD in the low,
intermediate, and high-risk groups were 3.5%  1.7%, 9.3% 
1.6%, and 19.3%  2.9%, respectively (P ¼ 1.9  105). The
corresponding CIs of 1-year NRM were 6.1%  2.2%, 13.1% 
1.9%, and 25.4%  3.2%, respectively (P ¼ 1.1  106). In a
further analysis, the variable ATG absent or at 2.5 mg/kg
versus 5 mg/kg was studied, and we found in multivariate
analysis that ATG absent or at 2.5mg/kg was a signiﬁcant risk
factor for SR aGVHD (HR, 2.54; P ¼ .001), again with MUD
(HR, 2.80; P ¼ .001) and FM (HR, 1.90; P ¼ .02).
Next, we asked if the identiﬁed pretransplantation risk
factors could also discriminate the risks of SR aGVHD in the
subgroups of patients with aGVHD grade II to IV (n ¼ 221) or
grade III and IV (n¼ 116). As shown in Table 5, the incidences
of SR aGVHD in both groups differed signiﬁcantly according
to the risk groups previously deﬁned.
DISCUSSION
In the present study, we report that MUD, FM, and
absence of ATG were independent risk factors for SR aGVHD
in adult patients who underwent transplantation with
matched related or unrelated donors at our center between
2000 and 2012. The deleterious impact of SR aGVHD on OS in
contrast to the effect of steroid-sensitive aGVHD supported
the rationale for speciﬁcally studying the risk factors for SR
aGVHD. The highest risk was observed in patients with 2 or 3
risk factors, with an incidence of SR aGVHD of 19.3%  2.9%
and a corresponding 1-year NRM of 25.4%  3.2%.Table 3
Multivariate Analysis of Risk Factors for SR aGVHD (n ¼ 630)
Variables HR 95% CI P Value
MUD 2.52 1.50-4.22 <.001
No ATG 2.02 1.23-3.32 .005
FM 1.84 1.09-3.11 .023
MAC regimen 1.06 .64-1.74 .82Several studies have compared outcomes of allo-SCT from
MUD and MRD. Two prospective nonrandomized studies
have been reported. The ﬁrst, conducted by the French
Society of Bone Marrow Transplantation and Cell Therapy,
included patients with standard-risk acute leukemia, chronic
myeloid leukemia, or myelodysplastic syndrome who
received a BM transplantation after a MAC regimen.
Transplants from MUD led to similar outcomes concerning
OS, NRM, and relapse, with trends for higher incidences of
aGVHD II to IV (HR,1.47; P¼ .064) and III and IV (HR,1.62; P¼
.108) [16]. The second study conducted by the German-
Austrian group in young adults with high-risk acute
myeloid leukemia in ﬁrst complete remission reported
similar OS and relapse rate [17]. Several retrospective studies
have also reported similar outcomes betweenMUD andMRD
concerning OS, relapse, and aGVHD [18-22]. However, other
retrospective studies have reported an increased incidence of
aGVHD after transplantations from MUD [23,24], with an
associated reduced OS in 2 studies [25,26]. Moreover, a large
recent study from the Fred Hutchinson Cancer Research
Center identiﬁed MUD as an independent risk factor for
aGVHD grade II to IV (HR, 1.66; P ¼ .001) [1]. Taken together,
these studies reported conﬂicting results about the impact of
MUD on the risk of aGVHD, likely reﬂecting differences in
population studies, transplantation procedures, and GVHD
prophylaxis. Of note, none of these studies had speciﬁcally
addressed the impact of donor type on the risk of SR aGVHD,
as reported in our study.
The effect of sex mismatching on transplantation out-
comes was reviewed by Garhton in 2007 [27]. Despite the
lack of prospective study, the available data suggested that
the combination of a female donor for a male recipient was a
risk factor for NRM because of a higher incidence of acute
and severe chronic GVHD [27]. Experimental data have
indeed demonstrated that Y chromosomeeencoded proteins
could serve as targets for female cytotoxic T lymphocytes
[28-30]. A more recent EBMT registry study of 53,988 pa-
tients reported increased incidences of aGVHD, extensive
chronic GVHD, and NRM (35.1% versus 30.2%; P ¼ .001) in
transplantations of male recipients with female donors, with
a greater increase in NRM than protection from relapse
(25.7% versus 27.7%; P¼ .001), leading to a net negative effect
on survival (43.2% versus 46.7%; P ¼ .001) [31]. Interestingly,
the large number of patients allowed the authors to compare
effects of female versus male alloreactivity in different sub-
populations and they reported that underlying disease had
no appreciable effect on the excess risk of NRM [31]. Our
ﬁnding that a female donor for a male recipient is an
Table 4
CI of SR aGVHD and NRM in the Whole Study Population in the Three Risk Groups
Risk Groups Risk Factors* No. of Patients SR aGVHDy NRMz
1-year 3-year
Low 0 115 3.5%  1.7% 6.1%  2.2% 10.9%  3%
Intermediate 1 323 9.3%  1.6% 13.1%  1.9% 16.7%  2.1%
High 2-3 192 19.3%  2.9% 25.4%  3.2% 31.4%  3.5%
* The 3 risk factors: MUD, FM, absence of ATG.
y P ¼ 1.9  105.
z P ¼ 1.1  106.
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these previously reported data. A recent EBMT study
reported that male recipients with acute leukemia who un-
derwent transplantation from MUD demonstrated a higher
risk of aGVHD compared with male recipients who under-
went transplantation from female MRD [32]. The survival
and leukemia-free survival were similar in both groups and
the authors concluded that a female MRD should be
preferred [32]. Our ﬁnding that MUD has a higher HR than
FM in multivariate analysis and is, thus, a more powerful risk
factor for SR aGVHD is in line with this recent study.
ATG is increasingly used before allo-SCT to reduce inci-
dence and severity of GVHD. A systematic review of ran-
domized controlled trials in the MAC setting by Kumar et al.
[33] reported no beneﬁt of ATG in OS (relative risk [RR], .91;
P ¼ .32), but a beneﬁt for the prevention of grade III to IV
aGVHD (RR, .51; P ¼ .03) without any signiﬁcant effect on
NRM (RR, .74; P ¼ .08) or relapse (RR, 1.19; P ¼ .44). These
results were independent of the source of ATG (rabbit versus
horse) [33]. Interestingly, a large retrospective study by the
Center for International Blood and Marrow Transplant
Research has recently challenged the use of ATG in the RIC
setting, reporting an increased relapse risk adversely
affecting OS [34]. In that study, disease-free survival was
lower with ATG compared with T cellereplete regimens (25%
versus 39%, P ¼ .001) and corresponding probabilities of OS
were 38% versus 46% (P ¼ .008). The high doses of rabbit ATG
(median 7 mg/kg) in that study might explain the results
[34]. The optimal dose and schedule of ATG remain contro-
versial, though the available retrospective data seem to favor
a dose of rabbit ATG (Thymoglobulin, Genzyme, Lyon, France)
of 4.5 to 6 mg/kg administered on the last few days before
transplantation, avoiding low doses (<3 mg/kg) probably
insufﬁcient to prevent aGVHD [35]. Our ﬁnding that the
absence of ATG is a risk factor for SR aGVHD is in line with
these previously reported results. The median dose of rabbit
ATG in our study was 5 mg/kg and our results suggest that a
dose protective against SR aGVHD should be 5 mg/kg.
However, this result must be taken with caution because of
the design of our study and because some doses (2.5 and 7.5
mg/kg) were exclusively used with RIC regimens.Table 5
CI of SR aGVHD in Patients with aGVHD Grade II to IV (n ¼ 221) or Grade III
and IV (n ¼ 116) in the Three Risk Groups
Risk Groups Risk
Factors*
aGVHD II-IV aGVHD III-IV
n SR aGVHDy n SR aGVHDz
Low 0 24 16.7%  7.8% 10 40%  16.6%
Intermediate 1 103 29.1%  4.5% 50 56%  7.1%
High 2-3 94 39.4%  5.1% 56 66.1%  6.4%
* The 3 risk factors: MUD, FM, absence of ATG.
y P ¼ .03.
z P ¼ .05.Our study has some limitations. First, the heterogeneity of
diseases and status at transplantation precluded a pertinent
analysis of relapse and disease-free survival. The time end-
points used for selection of SR aGVHD can be a matter of
debate despite the recent recommendations of EBMT-ELN
and ASBMT groups [5,12], as MacMillan et al. reported day
28 as a pertinent endpoint for aGVHD therapeutic trials in
predicting 2-year NRM [36]. Finally, the absence of available
pregnancy history in donors and the missing information on
donor ages precluded an analysis of these variables. Never-
theless, our data indicate that MUD, FM, and absence of ATG
are independent pretransplantation risk factors for SR
aGVHD in adult patients after allo-SCT from MRD or MUD.
In summary, our data identiﬁed an interesting group with
a very low risk of SR aGVHD (<5%) corresponding to patients
who underwent transplantation from MRD, with ATG, and
without the FM combination. Our results also suggest that
avoiding the FM combination and using ATG might protect
from a high risk of SR aGVHD (2 or 3 risk factors) after MUD
transplantations, whereas avoiding the FM combination and/
or using ATG might protect from the same risk after MRD
transplantations. As a consequence, in clinical practice, an
MRD should remain a priority as much as possible and we
would recommend to use ATG and to avoid a female donor
for a male recipient to lower the risk of SR aGVHD. In the
subgroup of patients with aGVHD, these risk factors also
identiﬁed high risk patients (2 or 3 risk factors) who might
be candidate for a risk-adapted ﬁrst-line treatment of aGVHD
evaluating an experimental drug in addition to the standard
ﬁrst-line combination of steroids and calcineurin inhibitors.
In this setting, the recent development of plasma biomarkers
as promising prognostic tools could interestingly complete
the information provided by our study [37].
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